ClinicalTrials.gg
CompletedNCT02597439PURPOSEUpdated Nov 17, 2026Results posted

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

A Phase 4 interventional study of Omega-3 fatty acids and Placebo in Ultra High Risk for Psychosis, sponsored by Rene Kahn. Completed at 14 sites in 9 countries. Open to participants aged 13 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Rene Kahn · Phase 4, Interventional, and Prevention

How we know

Updated Nov 17, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
13 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Psychotic Disorders with a site in Spain — 15 open to participants now, 19 under way, 4 of them phase 3. Psychotic Disorders · Spain.

Enrollment
26th of 49
146 · median 160
Started
2016
with 4 others
Phase 4
11 of 65
1 open now
Registered
20th of 65
by date
Lead sponsor
2 of 65
Rene Kahn

Among the 65 studies in Psychotic Disorders with a site in Spain, this one is the 26th largest by enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2016, is one of 11 in phase 4, and was the 20th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

15 of the 65 studies in Psychotic Disorders with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 13 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Psychotic Disorders with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.

Read the detailed description

PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 14 sites in 9 countries.

03

Conditions studied

  • Ultra High Risk for Psychosis

Browse trials for

Keywords

  • Ultra-high risk
  • UHR
  • psychosis
04

Who can participate

Ages eligible
13 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written of the subject. For individuals younger than 18 years of age the parents / legal representatives need to give consent, and the subject can provide assent (whether the latter is required depends on local laws and regulations).
  • UHR diagnosis as made using the Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic symptoms (a history of one or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) either the presence of schizotypal personality disorder or a family history of psychosis in a first-degree relative, all three together with a recent decline in function.

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that may influence the results of the trial or affect the ability to take part in a trial.
  • Laboratory screening values considered clinically relevant by a medical doctor for transaminases, thyroid hormones or coagulation parameters
  • Current or past diagnosis of psychosis, as measured with K-SADS-PL
  • Current treatment with an antipsychotic or mood-stabilising agent
  • Intake of an antipsychotic or mood-stabilising agent in the two weeks prior to study inclusion
  • Intake of an antipsychotic agent equivalent to a total haloperidol use of >50 mg in the six months prior to study inclusion
  • A first-degree relative (i.e. parents, offspring or siblings) participating in this study
  • UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely explained by acute intoxication
  • Current aggression or dangerous behaviour (PANSS G14 score 5 or above)
  • Current suicidality / self-harm (PANSS G6 score 7)
  • Current DSM-IV diagnosis of alcohol or substance dependence as measured with K-SADS-PL
  • Any current or previous neurological disorder, including epilepsy
  • History of head injury resulting in unconsciousness lasting at least 1 hour
  • IQ \< 70
  • More than 4 weeks of regular omega-3 supplementation (>2 daily capsules standard strength providing >600 mg combined EPA/DHA) within the last 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Active comparator
    Omega-3 fatty acids

    Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.

    Drug: Omega-3 fatty acids

  • Placebo comparator
    Placebo

    Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Transition Rate

    To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition).

    Time frame: measured starting from baseline up to 2 years post-baseline

Secondary outcomes

  1. Discontinuation Rate

    how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline)

    Time frame: measurement starting at baseline up to 2 years post-baseline

  2. Symptomatology

    change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms.

    Time frame: baseline to 2 years post-baseline

  3. Psychosocial Functioning

    Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning.

    Time frame: measurement started at baseline up to the 2 year timepoint

  4. Intelligence

    This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning

    Time frame: One time assessment of IQ

  5. Blood Levels of Bioactive Lipids

    Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline.

    Time frame: measurement started at baseline up until 6 months

  6. Positive and Negative Symptoms

    Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms.

    Time frame: from baseline to 2 years post-baseline

  7. Level of Functioning

    Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning.

    Time frame: from baseline to 2 years post-baseline

  8. Level of Depression

    Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms.

    Time frame: measured starting at baseline up to 2 years post-baseline

  9. Role Functioning

    Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction.

    Time frame: measurement started at baseline up until 2 years post-baseline

  10. Social Functioning

    Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation.

    Time frame: measurement started at baseline up until 2 years post-baseline

07

Results

Posted Nov 17, 2026
Limitations and caveats
Daily intake of PUFAs through diet was not measured, nor can the use of non-study omega-3 supplement in the placebo group be excluded.

Participant flow

Due to various difficulties, among which COVID, the goal of 220 randomized participants was not met.

Participant flow — Overall Study
MilestoneOmega-3 Fatty AcidsPlacebo
Started7175
Completed5657
Not completed1518

Outcome measures

PrimaryTransition Rate

To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition).

Time frame:
measured starting from baseline up to 2 years post-baseline
Reported as:
Count of participants · Participants
Transition Rate
ParticipantsOmega-3 Fatty AcidsPlacebo
Transition to psychosis53
Exceeding the maximally allowed dose of antipsychotics115
Not meeting endpoint criteria5160
SecondaryDiscontinuation Rate

how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline)

Time frame:
measurement starting at baseline up to 2 years post-baseline
Reported as:
Number · participants
Discontinuation Rate
participantsOmega-3 Fatty AcidsPlacebo
Discontinuation Rate2419
SecondarySymptomatology

change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms.

Time frame:
baseline to 2 years post-baseline
Reported as:
Mean · score
Symptomatology
scoreOmega-3 Fatty AcidsPlacebo
Symptomatology-0.234 (-0.316 to -0.152)0.0071 (0.0039 to 0.010)
SecondaryPsychosocial Functioning

Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning.

Time frame:
measurement started at baseline up to the 2 year timepoint
Reported as:
Mean · change in score
Psychosocial Functioning
change in scoreOmega-3 Fatty AcidsPlacebo
Psychosocial Functioning12.9 ± 9.013.7 ± 9.9
SecondaryIntelligence

This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning

Time frame:
One time assessment of IQ

Results for this outcome have not been posted.

SecondaryBlood Levels of Bioactive Lipids

Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline.

Time frame:
measurement started at baseline up until 6 months
Reported as:
Mean · umol/mmol Hb
Blood Levels of Bioactive Lipids
umol/mmol HbOmega-3 Fatty AcidsPlacebo
EPA3.4 ± 2.70.0 ± 0.6
DHA5.8 ± 5.0-0.7 ± 3.5
SecondaryPositive and Negative Symptoms

Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms.

Time frame:
from baseline to 2 years post-baseline
Reported as:
Mean · Total PANSS score
Positive and Negative Symptoms
Total PANSS scoreOmega-3 Fatty AcidsPlacebo
Positive and Negative Symptoms-7.2 ± 19.0-13.7 ± 14.2
SecondaryLevel of Functioning

Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning.

Time frame:
from baseline to 2 years post-baseline
Reported as:
Mean · GAF total score
Level of Functioning
GAF total scoreOmega-3 Fatty AcidsPlacebo
Level of Functioning7 ± 1.47.2 ± 1.5
SecondaryLevel of Depression

Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms.

Time frame:
measured starting at baseline up to 2 years post-baseline
Reported as:
Mean · Total score
Level of Depression
Total scoreOmega-3 Fatty AcidsPlacebo
Level of Depression-10.0 ± 6.4-11.9 ± 6.9
SecondaryRole Functioning

Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction.

Time frame:
measurement started at baseline up until 2 years post-baseline
Reported as:
Mean · GF Role total score
Role Functioning
GF Role total scoreOmega-3 Fatty AcidsPlacebo
Role Functioning0.9 ± 1.40.9 ± 1.5
SecondarySocial Functioning

Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation.

Time frame:
measurement started at baseline up until 2 years post-baseline
Reported as:
Mean · Total GF Social score
Social Functioning
Total GF Social scoreOmega-3 Fatty AcidsPlacebo
Social Functioning0.7 ± 1.41.0 ± 1.4

Adverse events

Collected over The period between randomization/baseline until 2 years post-baseline.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omega-3 Fatty Acids0/67 (0%)15/67 (22.4%)22/67 (32.8%)
Placebo0/68 (0%)13/68 (19.1%)12/68 (17.6%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventOmega-3 Fatty AcidsPlacebo
Exacerbation of depressive symptomsPsychiatric disorders3/671/68
Suicidal ideationPsychiatric disorders3/673/68
Suicide attemptPsychiatric disorders2/673/68
PregnancyPregnancy, puerperium and perinatal conditions2/670/68
AccidentInjury, poisoning and procedural complications1/670/68
Exacerbation of anxiety symptomsPsychiatric disorders1/671/68
Congenital heart defectCongenital, familial and genetic disorders1/670/68
Penis fractureReproductive system and breast disorders1/670/68
Biliary colicHepatobiliary disorders1/670/68
SeptoplastySurgical and medical procedures1/670/68
Most frequent other events
Most frequent other events
EventOmega-3 Fatty AcidsPlacebo
Nausea and VomitingGastrointestinal disorders9/673/68
Common ColdInfections and infestations7/672/68
Suicidal IdeationPsychiatric disorders6/677/68

Baseline characteristics

Eleven participants were excluded from the analyses due to not meeting inclusion criteria at baseline

Age, Continuous
Age, Continuous(years)Omega-3 Fatty AcidsPlaceboTotal
Mean16.3 ± 1.716.0 ± 1.816.1 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)Omega-3 Fatty AcidsPlaceboTotal
Female373875
Male303060
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Omega-3 Fatty AcidsPlaceboTotal
Ethnicity — White5858116
Ethnicity — Black202
Ethnicity — East Asian202
Ethnicity — Asian Indian101
Ethnicity — Middle Eastern134
Ethnicity — Other3710
Region of Enrollment
Region of Enrollment(participants)Omega-3 Fatty AcidsPlaceboTotal
Austria191938
Netherlands121325
Norway101
Italy101020
United Kingdom123
Israel426
Switzerland91120
Germany112
Spain101020
IQ
IQ(units on a scale)Omega-3 Fatty AcidsPlaceboTotal
Mean98.1 ± 17.7101.0 ± 18.599 ± 19
Major Depressive Disorder (current)
Major Depressive Disorder (current)(Participants)Omega-3 Fatty AcidsPlaceboTotal
Count of participants363268
Substance abuse and/or dependence in past 12 months
Substance abuse and/or dependence in past 12 months(Participants)Omega-3 Fatty AcidsPlaceboTotal
Count of participants459
Positive And Negative Symptoms Scale total score
Positive And Negative Symptoms Scale total score(units on a scale)Omega-3 Fatty AcidsPlaceboTotal
Mean59.0 ± 13.860.2 ± 15.159.6 ± 14.3

8 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • BioPsyC Biopsychosocial Corporation
    Vienna, Austria
  • Department of Child and Adolescent Psychiatry, University of Tübingen
    Tübingen, Germany
  • Schneider Children's Medical Center
    Petah Tikva, Israel
  • Tel Hashomer The Sheba Medical Center
    Ramat Gan, Israel
  • Fondazione Santa Lucia
    Rome, Italy
  • Sapienza University of Rome
    Rome, Italy
  • Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht
    Utrecht, Netherlands
  • Institute of Clinical Medicine, University of Bergen
    Bergen, Norway
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Infantil Passeig Sant Joan de Deu
    Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria
    Santander, Spain
  • ZKJP University Zürich
    Zurich, Switzerland
  • Psychiatry, Centre for Clinical Brain Sciences
    Edinburgh, United Kingdom
09

References and documents

Publications

  • Winter-van Rossum I, Slot MIE, van Hell HH, Bossong MG, Berger G, Aschauer H, Maat A, Walitza S, Lavan O, Baeza I, Dolz M, Monducci E, Fiori Nastro P, Kroken RA, Lawrie SM, Diaz-Caneja CM, Renner T, Schlogelhofer M, Scharinger C, Spalletta G, Banaj N, Otero S, Schipper M, Kwakkel DB; PURPOSE Study Group; Kahn RS. Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial. Schizophr Bull. 2025 Jul 7;51(4):1082-1091. doi: 10.1093/schbul/sbae186. PubMed 39450759 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Feb 2023, 76 months.

Results were first posted in Nov 2026, 3 years 9 months after primary completion.

Of 45 non-industry phase 4 interventional studies under Psychotic Disorders, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 71. This study's 76 months is above that.

Counting every sponsor, half of 51 studies reached it within 58 months; a quarter within 32 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2015
First posted
Nov 5, 2015
StartActual
Sep 30, 2016
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Sites
1 site added, 1 site removed
Show site
  • Schneider Children's Medical Center · Petah Tikva, Israel
Show 1 removed
  • Schneider Children's Medical Center · Petach Tikva, Israel
Nov 17, 2026
Enrollment
145→146
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTransition rateRateTime frame: 2 years → measured starting from baseline up to 2 years post-baseline
Nov 17, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39450759 ↗
Nov 17, 2026
Secondary outcomes
8 edited, 1 time frame changed, 1 added, 6 removed, 1 description edited
What changed in the outcomes
  • EditedDiscontinuation rateRateTime frame: 2 years → measurement starting at baseline up to 2 years post-baseline
  • EditedPsychosocial functioningFunctioningTime frame: 2 years → measurement started at baseline up to the 2 year timepoint
  • EditedBlood levelsLevels of bioactive lipidsBioactive LipidsTime frame: 2 years → measurement started at baseline up until 6 months
  • EditedPositive and negative symptomsNegative SymptomsTime frame: 2 years → from baseline to 2 years post-baseline
  • EditedLevel of functioningFunctioningTime frame: 2 years → from baseline to 2 years post-baseline
  • EditedLevel of depressionDepressionTime frame: 2 years → measured starting at baseline up to 2 years post-baseline
  • EditedRole functioningFunctioningTime frame: 2 years → measurement started at baseline up until 2 years post-baseline
  • EditedSocial functioningFunctioningTime frame: 2 years → measurement started at baseline up until 2 years post-baseline
  • AddedIntelligenceTime frame: One time assessment of IQ
  • RemovedCognitive functionTime frame: 2 years
  • RemovedMRI measuresTime frame: 2 years
  • RemovedTolerability associated with omega-3 fatty acid treatmentTime frame: 2 years
  • RemovedBlood levels of (epi)genetic markersTime frame: 2 years
  • RemovedBlood levels of immune parametersTime frame: 2 years
  • RemovedClinical ImpressionTime frame: 2 years
  • Time frameSymptomatology2 years → baseline to 2 years post-baseline
  • DescriptionSymptomatology: how it is measured was reworded
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39450759 ↗
    1 site added, 1 site removed
    Show site
    • Schneider Children's Medical Center · Petah Tikva, Israel
    Show 1 removed
    • Schneider Children's Medical Center · Petach Tikva, Israel
    Enrollment 145→146
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTransition rateRateTime frame: 2 years → measured starting from baseline up to 2 years post-baseline
    Secondary outcomes 8 edited, 1 time frame changed, 1 added, 6 removed, 1 description edited
    What changed in the outcomes
    • EditedDiscontinuation rateRateTime frame: 2 years → measurement starting at baseline up to 2 years post-baseline
    • EditedPsychosocial functioningFunctioningTime frame: 2 years → measurement started at baseline up to the 2 year timepoint
    • EditedBlood levelsLevels of bioactive lipidsBioactive LipidsTime frame: 2 years → measurement started at baseline up until 6 months
    • EditedPositive and negative symptomsNegative SymptomsTime frame: 2 years → from baseline to 2 years post-baseline
    • EditedLevel of functioningFunctioningTime frame: 2 years → from baseline to 2 years post-baseline
    • EditedLevel of depressionDepressionTime frame: 2 years → measured starting at baseline up to 2 years post-baseline
    • EditedRole functioningFunctioningTime frame: 2 years → measurement started at baseline up until 2 years post-baseline
    • EditedSocial functioningFunctioningTime frame: 2 years → measurement started at baseline up until 2 years post-baseline
    • AddedIntelligenceTime frame: One time assessment of IQ
    • RemovedCognitive functionTime frame: 2 years
    • RemovedMRI measuresTime frame: 2 years
    • RemovedTolerability associated with omega-3 fatty acid treatmentTime frame: 2 years
    • RemovedBlood levels of (epi)genetic markersTime frame: 2 years
    • RemovedBlood levels of immune parametersTime frame: 2 years
    • RemovedClinical ImpressionTime frame: 2 years
    • Time frameSymptomatology2 years → baseline to 2 years post-baseline
    • DescriptionSymptomatology: how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02597439
Lead sponsor
Rene Kahn
Responsible party
Rene Kahn (Prof. dr., UMC Utrecht) — Sponsor-investigator
First posted
Nov 5, 2015
Start date
Sep 30, 2016
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

René Kahn, Prof. Dr.
study chair · UMC Utrecht

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion